



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Pascale Pouzet et al  
Serial No. : 10/058,456  
Filed : January 28, 2002  
For : Alkylphenyliminoimidazolidine Derivatives for Treating Urinary  
Incontinence

Docket No.: 1/1168  
) Art Unit: to be assigned  
) Examiner: to be assigned

Office of Initial Patent Examination's  
Customer Service Center  
Assistant Commissioner for Patents  
Washington, DC 20231

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Sir:

The undersigned respectfully requests correction of the Filing Receipt for  
Application Number 10/058,456.

Please correct the resident city of the sixth named inventor (Ikunobu  
Muramatsu) from "Yoshida-gun" to --Hyogo--, as noted on the attached copy of the  
Official Filing Receipt.

The undersigned hereby requests that the United States Patent and Trademark  
Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Timothy X. Witkowski  
Registration No. 40,232

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT 06877  
Tel: (203) 798-4310  
Date: March 14, 2002  
Docket No.: 1/1168



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/058,456	01/28/2002	1614	920	1/1168		30	3

CONFIRMATION NO. 4239

## FILING RECEIPT



\*OC000000007532429\*


28501  
BOEHRINGER INGELHEIM CORPORATION  
900 RIDGEBURY ROAD  
P. O. BOX 368  
RIDGEFIELD, CT 06877

Date Mailed: 02/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Pascale Pouzet, Biberach, GERMANY;  
Franz Esser, Ingelheim, GERMANY;  
Matthias Hoffmann, Mittelbiberach, GERMANY;  
Hisato Kitagawa, Osaka, JAPAN;  
Kenji Sakai, Hyogo, JAPAN;  
Ikunobu Muramatsu, ~~Yoshida-gun~~, JAPAN;  
Hyogo



## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/270,333 02/21/2001

## Foreign Applications

GERMANY 101 06 214.1 02/10/2001

If Required, Foreign Filing License Granted 02/25/2002


Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

## Title

Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence



**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).